Notably, both selumetinib and MSU-42011, alone and in combination, reduced Il-6 mRNA expression by 52.76% (p = 0.0007), 63.12% (p < 0.0001), and 54.26% (p = 0.0005) compared with vehicle treatment, as measured in tumor lysates (Figure 2C). This evidence concerns the gene IL6 and neoplasm.